Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
CHORDOMES
1 other identifier
observational
40
1 country
1
Brief Summary
Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of chordomas is basically not known. Similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like CDX2, INSM1 and FOXA1, which remains unknown for chordomas. Thus, the aim of the study is to explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2020
CompletedFirst Submitted
Initial submission to the registry
July 22, 2020
CompletedFirst Posted
Study publicly available on registry
July 27, 2020
CompletedJuly 27, 2020
July 1, 2020
3 months
July 22, 2020
July 22, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Expression of PD-L1
measured by immunohistochemical method
Baseline
Expression of CD8
measured by immunohistochemical method
Baseline
Expression of CDX2
measured by immunohistochemical method
Baseline
Expression of INSM1
measured by immunohistochemical method
Baseline
Expression of FOXA1
measured by immunohistochemical method
Baseline
Secondary Outcomes (3)
Histological type of tumor
Baseline
Tumor location
Baseline
survival of patients after diagnosis with or without progression
Baseline
Study Arms (1)
Chordoma
Patients diagnosed with chordoma
Interventions
Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
Eligibility Criteria
Patients diagnosed with chordoma
You may qualify if:
- Patients diagnosed with chordoma
- Sufficient histological material available
- Tumor expression of brachyury
You may not qualify if:
- \- Insufficient histological material
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Saint-Etienne
Saint-Etienne, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Georgia KARPATHIOU, MD
CHU SAINT-ETIENNE
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 22, 2020
First Posted
July 27, 2020
Study Start
April 1, 2020
Primary Completion
July 1, 2020
Study Completion
July 1, 2020
Last Updated
July 27, 2020
Record last verified: 2020-07
Data Sharing
- IPD Sharing
- Will not share